U.S. FDA Refuses To Release Names Of Chinese Heparin Suppliers
This article was originally published in PharmAsia News
The U.S. FDA refuses to supply a congressional committee a list of the Chinese companies that supply the active ingredient heparin used in blood-clotting drugs. Congressional investigators want to explore the agency's handling of drug imports in the wake of the tainted heparin problem believed the cause of several U.S. deaths. The FDA said it cannot release the names of the Chinese companies because it has confidentiality agreements with drug manufacturers. Members of Congress believe Chinese drug makers did not cooperate fully with the U.S. FDA's own investigation. (Click here for more - a subscription may be required
You may also be interested in...
Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.
Diabetes company Dexcom said it expects 2020 revenues to reach $1.85bn driven by new patient adoption of its continuous glucose monitoring (CGM) system including by people with type 2 diabetes. See what SVB Leerink analyst Danielle Antalffy said about Dexcom’s earnings results here.